Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide
| Autor: | Takehito Miura, Hajime Fujii, Kuniyoshi Tajima, Yukiko Fukuchi, Reiki Ishizuka |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Combined use Cancer therapy Cancer Genistein medicine.disease Surgery chemistry.chemical_compound Quality of life chemistry Internal medicine Active hexose correlated compound medicine business Adverse effect |
| Zdroj: | Personalized Medicine Universe. 1:39-44 |
| ISSN: | 2186-4950 |
| DOI: | 10.1016/j.pmu.2012.05.006 |
| Popis: | This study aims to provide a strategy for personalized cancer therapy that results in increased survival time with better and more stable quality of life (QOL). Methods and patients Active hexose correlated compound (AHCC) and genistein concentrated polysaccharide (GCP) were administered to patients diagnosed with stage IV non-small cell lung cancer (NSCLC) with distant metastasis (M1). AHCC and GCP were consumed orally by concurrent or sequential use. Long-term follow-up study was conducted from January 1996 to January 2012 using the individualized evidence-based medicine (EBM) approach. Forty-two cases of NSCLC were enrolled in this study. Results The cumulative survival rate after 1, 2, 3, 4, and 5 years of treatment were 80.6%, 56.8%, 24.3%, 8.1%, and 5.4%, respectively. Median survival time (MST) was relatively longer at 28.26 months, as compared to that of current cancer therapies that solely involve chemotherapy. Evaluation of QOL showed that 40% of the 42 M1 cases achieved excellent (Class A) and good (Class B) QOL according to our 5-level QOL scoring. Conclusions AHCC and GCP resulted in increased patient survival time, better QOL, and reduced adverse effects related to cancer chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|